Productos destacados
Soluciones Innovadoras para Profesionales Sanitarios.
Secciones destacadas
Referencias
- GSK Data on File. Document number 2019N409506_00, junio 2019.
- Shingrix - Información para prescribir aprobada en CARICAM.
- Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek JAR, Richardus JH, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine. 2014 Mar;32(15):1745-53.
- Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015 May;372(22):2087-96.
- Bharucha T, Ming D, Breuer J. A critical appraisal of ‘Shingrix’, a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus. Hum Vaccin Immunother. 2017 Aug;13(8):1789-97.
- Merck Sharp & Dohme. Merck Zoster Vaccine European public assessment report, Annex I: Summary of product characteristics: EMA; [updated January 2019; accessed May 2020]. Available from: https://www.ema.europa.eu/en/documents/product-information/zostavax-epar-product-information_en.pdf.
- Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol. 2012 Aug;24(4):494-500.
PM-RCH-NA-WCNT-210003
Fecha de preparación Diciembre 2024 | Fecha de expiración Diciembre 2026.